Anagrelide represses GATA‐1 and FOG‐1 expression without interfering with thrombopoietin receptor signal transduction

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1538-7836.2010.03970.xPMID 20586925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic Analysis of Hierarchical Regulation for Gata1 and NF-E2 p45 Gene Expression in Megakaryopoiesis

  2010cited by this paper
• The mitogen‐activated protein kinase signaling pathways: role in megakaryocyte differentiation

  2010cited by this paper
• GATA-2 Reinforces Megakaryocyte Development in the Absence of GATA-1

  2009cited by this paper
• A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis.

  2009cited by this paper
• GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia

  2008cited by this paper
• The Protein Kinase C (PKC) Family of Proteins in Cytokine Signaling in Hematopoiesis

  2007cited by this paper
• Transcriptional control of megakaryocyte development

  2007cited by this paper
• Analysis of Relative Gene Expression Data Using Real-time Quantita- Tive Pcr and the 2 Preanalytic Error Tracking in a Laboratory Medicine Department: Results of a 1-year Experience

  2006cited by this paper
• Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage

  2006cited by this paper
• A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions.

  2006cited by this paper
• Effects of anagrelide on megakaryopoiesis and platelet production.

  2006cited by this paper
• Redirecting differentiation of hematopoietic progenitors by a transcription factor, GATA-2.

  2006cited by this paper
• Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins.

  2005cited by this paper
• The molecular mechanisms that control thrombopoiesis.

  2005cited by this paper
• Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures

  2005cited by this paper
• Differential signalling of NH2-terminal flag-labelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies.

  2004cited by this paper
• A long-term study of young patients with essential thrombocythemia treated with anagrelide.

  2004cited by this paper
• Article Title: RUNX1 and GATA -1 Coexpression and Cooperation in Megakaryocytic Differentiation

  2003cited by this paper
• Thrombopoietin: a tool for understanding thrombopoiesis

  2003cited by this paper
• Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review

  2002cited by this paper
• Lysophosphatidylcholine Inhibits Insulin-Induced Akt Activation Through Protein Kinase C-&agr; in Vascular Smooth Muscle Cells

  2002cited by this paper
• Transcriptional regulation of erythropoiesis: an affair involving multiple partners

  2002cited by this paper
• Control of megakaryocyte‐specific gene expression by GATA‐1 and FOG‐1: role of Ets transcription factors

  2002cited by this paper
• Thrombopoietin-Mediated Sustained Activation of Extracellular Signal-Regulated Kinase in UT7-Mpl Cells Requires Both Ras–Raf-1- and Rap1–B-Raf-Dependent Pathways

  2001cited by this paper
• Long-term use of anagrelide in young patients with essential thrombocythemia.

  2001cited by this paper
• Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo)

  2001cited by this paper
• Molecular and Transcriptional Regulation of Megakaryocyte Differentiation

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• FLI-1 is a suppressor of erythroid differentiation in human hematopoietic cells

  2000cited by this paper
• Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia.

  2000cited by this paper
• The GATA-1 and Spi-1 transcriptional factors bind to a GATA/EBS dual element in the Fli-1 exon 1

  1999cited by this paper
• Protein Kinase Cζ Is a Negative Regulator of Protein Kinase B Activity*

  1999cited by this paper
• Thrombopoietin.

  1998cited by this paper
• Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells.

  1998cited by this paper
• Inhibition of erythroid differentiation and induction of megakaryocytic differentiation by thrombopoietin are regulated by two different mechanisms in TPO-dependent UT-7/c-mpl and TF-1/c-mpl cell lines

  1998cited by this paper
• FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation.

  1997cited by this paper
• A lineage‐selective knockout establishes the critical role of transcription factor GATA‐1 in megakaryocyte growth and platelet development

  1997cited by this paper
• Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha.

  1997cited by this paper
• The effects of anagrelide on human megakaryocytopoiesis

  1997cited by this paper
• Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes.

  1996cited by this paper
• Thrombopoietin activates a STAT5‐like factor in hematopoietic cells.

  1995cited by this paper
• Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2.

  1995cited by this paper
• Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development.

  1995cited by this paper
• Megakaryocytic differentiation induced in 416B myeloid cells by GATA-2 and GATA-3 transgenes or 5-azacytidine is tightly coupled to GATA-1 expression.

  1993cited by this paper
• Murine c‐mpl: a member of the hematopoietic growth factor receptor superfamily that transduces a proliferative signal.

  1993cited by this paper
• Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.

  1992cited by this paper
• Anagrelide: a new drug for treating thrombocytosis.

  1988cited by this paper

• Determination of Structural Factors Contributing to Protection of Zinc Fingers in Estrogen Receptor α through Molecular Dynamic Simulations

  2025cites this paper
• Essential Thrombocythemia: A Review.

  2025cites this paper
• Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis

  2024cites this paper
• A Case of acute Myocardial Infarction in a Patient with Essential Thrombocythaemia Treated with Anagrelide

  2024cites this paper
• Anagrelide: A Clinically Effective cAMP Phosphodiesterase 3A Inhibitor with Molecular Glue Properties.

  2023cites this paper
• Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review

  2022cites this paper
• Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.

  2022cites this paper
• Antagonistic L1 Adhesion Molecule Mimetic Compounds Inhibit Glioblastoma Cell Migration In Vitro

  2022cites this paper
• Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose

  2022cites this paper
• Acute Myocardial Infarction in an Adolescent Receiving Anagrelide for Essential Thrombocythemia with Underlying Persistent Coronary Endothelial Dysfunction.

  2020cites this paper
• Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day

  2020cites this paper
• Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets

  2019cites this paper
• Anagrelide is an anti-megakaryocytic and not an anti-platelet agent

  2018cites this paper
• Skewed megakaryopoiesis in human induced pluripotent stem cell‐derived haematopoietic progenitor cells harbouring calreticulin mutations

  2018cites this paper
• Highlights of the 2nd International Symposium on Tribbles and Diseases: tribbles tremble in therapeutics for immunity, metabolism, fundamental cell biology and cancer

  2018cites this paper
• Spotlight on anagrelide hydrochloride for the treatment of essential thrombocythemia

  2017cites this paper
• Pharmacokinetics of a Novel Anagrelide Extended‐Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product

  2017cites this paper
• Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis

  2017cites this paper
• Inhibition of human primary megakaryocyte differentiation by anagrelide: a gene expression profiling analysis

  2016cites this paper
• The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia

  2016cites this paper
• Anagrelide platelet‐lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms

  2015cites this paper
• Advances and challenges in the management of essential thrombocythemia

  2015cites this paper
• Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide

  2015cites this paper
• The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis

  2015cites this paper
• The Characterization of the Interaction Between Phosphodiesterase 3A and Compound 1B, a Novel Selective Cytotoxic Agent

  2014cites this paper
• Effect of anagrelide on cardiac repolarization in healthy volunteers: a randomized, double‐blind, placebo‐ and positive‐controlled, thorough QT study

  2014cites this paper
• The Characterization of the Interaction Between Phosphodiesterase 3A and Compound 1B, a Novel Selective Cytotoxic Agent

  2014cites this paper
• Anagrelide hydrochloride for essential thrombocythemia

  2013cites this paper
• Synthesis and stability of 3-hydroxyanagrelide, a biologically potent metabolite of anagrelide

  2012cites this paper
• SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence

  2012cites this paper